<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00301860</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000462439</org_study_id>
    <secondary_id>UCSF-02164</secondary_id>
    <secondary_id>UCSF-H10216-21819-03</secondary_id>
    <nct_id>NCT00301860</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer</brief_title>
  <official_title>Feasibility of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions for Children at High Risk for Complications With Conventional Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor peripheral blood stem cell transplant helps&#xD;
      stop both the growth of cancer cells and the patient's immune system from rejecting the&#xD;
      donor's stem cells. When the healthy stem cells from a donor are infused into the patient,&#xD;
      they may help the patient's bone marrow make stem cells, red blood cells, white blood cells,&#xD;
      and platelets. Sometimes the transplanted cells from a donor can make an immune response&#xD;
      against the body's normal cells. Giving chemotherapy, such as fludarabine and melphalan, and&#xD;
      antithymocyte globulin before transplant and cyclosporine and methotrexate after transplant&#xD;
      may stop this from happening.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well donor stem cell transplant, using low-dose&#xD;
      chemotherapy and antithymocyte globulin, followed by donor white blood cell infusions work in&#xD;
      treating young patients with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of allogeneic hematopoietic stem cell transplantation using a&#xD;
           reduced-intensity conditioning regimen, in terms of whole blood engraftment rate at 100&#xD;
           days post transplant, in pediatric patients with hematopoietic malignancies who are at&#xD;
           high risk for complications with conventional transplantation.&#xD;
&#xD;
        -  Determine the feasibility of donor lymphocyte infusions (DLIs), in terms of number of&#xD;
           patients who receive at least one DLI by 12 months post transplant, in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the toxicities of the conditioning regimen, in terms of 100-day post&#xD;
           transplant nonrelapse-related death rate, in these patients.&#xD;
&#xD;
        -  Determine the toxicity of DLI, in terms of acute and chronic graft-vs-host disease rate&#xD;
           and 12-month post transplant nonrelapse-related death rate, in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Reduced-intensity conditioning regimen: Patients receive fludarabine IV on days -6 to&#xD;
           -2; antithymocyte globulin IV on days -5 to -2; and melphalan IV on days -3 and -2.&#xD;
&#xD;
        -  Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation&#xD;
           on day 0. Patients also receive filgrastim (G-CSF) IV beginning on day 5 and continuing&#xD;
           until blood counts recover.&#xD;
&#xD;
        -  Graft-vs-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV or orally&#xD;
           beginning on day -1 and continuing until at least day 28 and methotrexate IV on days 1,&#xD;
           3, and 6.&#xD;
&#xD;
        -  Donor lymphocyte infusion (DLI): Patients with mixed chimerism, no acute GVHD requiring&#xD;
           therapy, and no relapse/progression post transplant at day 90 may receive DLI. At least&#xD;
           30 days after discontinuation of immunosuppression, patients may receive up to 2 DLIs at&#xD;
           least 8-12 weeks apart in the absence of GVHD.&#xD;
&#xD;
      At the completion of study treatment, patients are followed periodically for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of efficacy&#xD;
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">8</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following hematopoietic malignancies:&#xD;
&#xD;
               -  Acute lymphoblastic leukemia or myeloid leukemia with &lt; 30% blasts in the bone&#xD;
                  marrow&#xD;
&#xD;
               -  Juvenile myelomonocytic leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia in chronic or accelerated phase&#xD;
&#xD;
               -  Relapsed non-Hodgkin's or Hodgkin's lymphoma in at least partial remission&#xD;
&#xD;
          -  Considered at high risk (&gt; 30%) of toxic death with standard hematopoietic stem cell&#xD;
             transplantation (HSCT), as indicated by at least one of the following:&#xD;
&#xD;
               -  Creatinine &gt; 1.5 times normal OR creatinine clearance &lt; 70 mL/min OR tubular&#xD;
                  damage that is not corrected by cessation of chemotherapy&#xD;
&#xD;
               -  DLCO &lt; 60% of predicted OR history of prior intubation due to lung disease&#xD;
                  (intubation for surgery excluded)&#xD;
&#xD;
               -  Shortening fraction &lt; 30%&#xD;
&#xD;
               -  History of disseminated fungal infection during chemotherapy OR currently&#xD;
                  receiving antifungal agents OR history of â‰¥ 2 septic episodes (confirmed by&#xD;
                  cultures) that required ICU support&#xD;
&#xD;
                    -  Patients with improving fungal or other infections eligible&#xD;
&#xD;
                         -  Improving infection is defined as confirmed negative cultures on 2&#xD;
                            separate occasions, at least 1 week apart, and/or stable or improving&#xD;
                            imaging studies (e.g., CT scan) of the infected site&#xD;
&#xD;
                         -  Two imaging studies taken at least 2 weeks apart must show stable or&#xD;
                            improved disease&#xD;
&#xD;
               -  History of stroke or abnormal MRI/MRA OR leukoencephalopathy OR seizures that are&#xD;
                  not fully controlled with anticonvulsants (&gt; 2 episodes of seizures in the&#xD;
                  preceding year or 1 episode of status epilepticus in a patient who is receiving&#xD;
                  anticonvulsant therapy)&#xD;
&#xD;
               -  History of prior significant bleeding (e.g., pulmonary, CNS, or gastrointestinal)&#xD;
                  OR history of a clotting disorder as manifested by prior significant thromboses&#xD;
                  (e.g., superior vena cava, inferior vena cava, or femoral vein)&#xD;
&#xD;
          -  Failed conventional therapies and not eligible for myeloablative protocols&#xD;
&#xD;
               -  May have failed prior conventional HSCT&#xD;
&#xD;
          -  No active CNS leukemia&#xD;
&#xD;
          -  Unrelated or related donor available, meeting the following criteria:&#xD;
&#xD;
               -  Matched for at least 7/8 loci by high-resolution typing&#xD;
&#xD;
               -  One mismatch at A, B, or C loci allowed&#xD;
&#xD;
               -  Fully matched at DRB1 locus&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%&#xD;
&#xD;
          -  No active/progressing viral, bacterial, protozoal, or fungal infection&#xD;
&#xD;
          -  Transaminases â‰¤ 5 times normal (except in the presence of autoimmune liver disease)&#xD;
&#xD;
          -  Shortening fraction â‰¥ 25%&#xD;
&#xD;
          -  DLCO â‰¥ 40% OR pulse oximetry â‰¥ 85% on room air&#xD;
&#xD;
          -  Glomerular filtration rate â‰¥ 40 mL/min&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior prolonged intensive chemotherapy (&gt; 3 years of therapy or â‰¥ 3 different&#xD;
             chemotherapeutic protocols) allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biljana Horn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>March 9, 2006</study_first_submitted>
  <study_first_submitted_qc>March 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2006</study_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

